Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
4 evidence topics · 4 sources
Add-on to standard of care in the phase 3 trial
Background antihypoglycemic therapies weaned during expanded access
Tumor-directed therapies given with ersodetug
“Within 8 weeks of ersodetug initiation, nearly all individuals (n = 7) were able to proceed with tumor-directed therapies, including chemotherapy (n = 7), surgery (n = 4), and other medical procedures such as hepatic arterial embolization (n = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote